%0 Journal Article
%T Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis
%A Eliana Krulig
%A Kenneth B Gordon
%J Core Evidence
%D 2010
%I 
%R http://dx.doi.org/10.2147/CE.S5994
%X tekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis Review (2985) Total Article Views Authors: Eliana Krulig, Kenneth B Gordon Published Date July 2010 Volume 2010:5 Pages 11 - 22 DOI: http://dx.doi.org/10.2147/CE.S5994 Eliana Krulig, Kenneth B Gordon NorthShore University HealthSystem, University of Chicago, Pritzker School of Medicine, Skokie, IL, USA Introduction: Psoriasis is a chronic inflammatory skin disease affecting approximately 2% to 3% of the population worldwide. Discoveries over the past 3 to 5 years have significantly altered our view of psoriasis as primarily a T-cell mediated condition. The most recent research has demonstrated the essential role of specific cytokines in the development of this complex disease, including TNF- , interleukin-23 (IL-23), and potentially, IL-22. These are all part of a newly defined autoimmune pathway directed by specialized T cells called Th17 helper T cells. Ustekinumab is a fully human monoclonal antibody that targets IL-12 and IL-23, thus targeting both Th1 and Th17 arms of immunity. It has a promising efficacy and safety profile that not only represents a valuable treatment alternative, but also a continuation in our constantly evolving understanding of this disorder. Aims: To review the emerging evidence supporting the use of ustekinumab in the management of moderate to severe plaque psoriasis. Evidence review: There is clear evidence that ustekinumab is effective in the treatment of moderate to severe psoriasis. Phase III trials (PHOENIX 1 and 2) demonstrated a statistically significant difference between Psoriasis Area and Severity Index (PASI) 75 responses achieved by patients receiving ustekinumab, given as a 45 mg or 90 mg subcutaneous injection every 12 weeks, than their placebo counterparts. Treatment with this novel agent resulted in a rapid onset of action, with over 60% of treated patients attaining Physician¡¯s Global Assessment (PGA) scores of ¡°cleared¡± or ¡°minimal¡± by week 12. Quality of life assessments paralleled clinical improvements. Clinical potential: Ustekinumab is an effective and efficient therapeutic option for patients with moderate to severe psoriasis. Although further studies are required to establish ustekinumab¡¯s place in the therapy of psoriasis, with its convenient dosing schedule and rapid onset of action, this drug could provide a great addition to the current therapeutic armamentarium available for psoriatic patients.
%K ustekinumab
%K psoriasis
%K biologics
%K interleukin-12 (IL-12)
%K interleukin-23 (IL-23)
%K IL-12/23
%K evidence
%U https://www.dovepress.com/ustekinumab-an-evidence-based-review-of-its-effectiveness-in-the-treat-peer-reviewed-article-CE